Replies to post #99973 on Ayala Pharmaceuticals Inc (ADXS)

[raja48185]

Estimated over $500M market potential in cervical cancer alone"

They estimate AXAL cervical alone has this much potential.

Talk is cheap, especially coming from ADXS management. What did DOC say about ADXS potential - that it is going to be a 6 billion dollar company. What was HER2 Potential? Each of the HOT indicators and NEO.

What are they delivering, other than 'Dilution' and 'Nothing' ?

Are the ph3 results sufficient to push this to ph4 and something that can be marketable or not?

Good Question. Another question worth asking is ' Why is BP not interested in ADXS even at this low MC?

[Bourbon_on_my_cornflakes]

"Estimated over $500M market potential in cervical cancer alone"

That's just for India alone, right? Remember the Biocon deal DOC signed. Biocon was going to have us approved there by 2018, so we are swimming in revenues, correct?

[cdiddy01]

If it is worth 500 million this share price should be at least 15-20$, but its not. Why do they state this and at the same time say they are trying to offload.

To keep you and I guessing and to keep retail heavily involved.

[mypekeispooped]

AXAL, by itself, has been shown as a safe, effective therapy for cervical cancer. I imagine a triple combo with chemo, an anti-PD-1 agent and AXAL would have a synergistic effect. Merck seems to want throw Keytruda at every cancer and has already been approved for cervical in a second-line setting. It would take little money on Mercks part to license this application from Advaxis. They could possibly move from a PI (if promising) to a P3 fairly quickly. I am puzzled they have not, as yet, done so. IMHO